TAVT-135

TAVT-135 is an inhaled peptide-small molecule conjugate being developed by Tavanta Therapeutics as a pan-genotypic treatment for cystic fibrosis. It functions as an artificial chloride ion transporter, a unique mechanism designed to restore chloride ion balance across cell membranes in the airways. By facilitating chloride transport, TAVT-135 aims to prevent the thickening and accumulation of mucus, thereby slowing the progressive deterioration of lung function associated with cystic fibrosis. Initial preclinical studies have demonstrated its ability to transport chloride ions without significant cell toxicity, offering a potential therapeutic option for all cystic fibrosis patients regardless of their specific CFTR mutation.